Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: results from two phase III, randomized, vehicle-controlled studies
Top Cited Papers
- 1 May 2004
- journal article
- clinical trial
- Published by Elsevier in Journal of the American Academy of Dermatology
- Vol. 50 (5) , 722-733
- https://doi.org/10.1016/j.jaad.2003.11.066
Abstract
No abstract availableKeywords
This publication has 10 references indexed in Scilit:
- Imiquimod 5% cream for the treatment of superficial and nodular basal cell carcinoma: randomized studies comparing low-frequency dosing with and without occlusionBritish Journal of Dermatology, 2002
- Efficacy of Topical 5% Imiquimod Cream for the Treatment of Nodular Basal Cell CarcinomaArchives of Dermatology, 2002
- Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: A double-blind, randomized, vehicle-controlled study*Journal of the American Academy of Dermatology, 2002
- Plasmacytoid dendritic cells produce cytokines and mature in response to the TLR7 agonists, imiquimod and resiquimodCellular Immunology, 2002
- Small anti-viral compounds activate immune cells via the TLR7 MyD88–dependent signaling pathwayNature Immunology, 2002
- Imiquimod 5% cream in the treatment of superficial basal cell carcinoma: Results of a multicenter 6-week dose-response trialJournal of the American Academy of Dermatology, 2001
- Therapeutic response of basal cell carcinoma to the immune response modifier imiquimod 5% creamJournal of the American Academy of Dermatology, 1999
- Review Article Imiquimod applied topically: a novel immune response modifier and new class of drugInternational Journal of Immunopharmacology, 1999
- Interval estimation for the difference between independent proportions: comparison of eleven methodsStatistics in Medicine, 1998
- Two-sided confidence intervals for the single proportion: comparison of seven methodsStatistics in Medicine, 1998